GCP
ABEO icon

GSA Capital Partners’s Abeona Therapeutics ABEO Stock Holding History

GSA Capital Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63,835
Closed -$304K – 1698
2025
Q1 		$304K Sell
63,835
-42,690
-40% -$232K 0.03% 1141
2024
Q4 		$593K Buy
106,525
+10,433
+11% +$64.2K 0.04% 758
2024
Q3 		$607K Buy
96,092
+33,831
+54% +$177K 0.05% 795
2024
Q2 		$264K Buy
62,261
+37,700
+153% +$192K 0.02% 1335
2024
Q1 		$178K Buy
+24,561
New +$156K 0.01% 1426
2023
Q4 		– Sell
-11,638
Closed -$49K – 1439
2023
Q3 		$49K Buy
+11,638
New +$44K ﹤0.01% 1419
2022
Q1 		– Sell
-31,523
Closed -$266K – 1359
2021
Q4 		$266K Buy
31,523
+30,184
+2,254% +$554K 0.03% 1024
2021
Q3 		$37K Buy
+1,339
New +$42.9K ﹤0.01% 1355
2020
Q4 		– Sell
-444
Closed -$11K – 1154
2020
Q3 		$11K Buy
+444
New +$28K ﹤0.01% 1222
2019
Q3 		– Sell
-805
Closed -$96K – 1352
2019
Q2 		$96K Buy
+805
New +$135K 0.01% 1345

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

GSA Capital Partners's ABEO Position: Q2 2025 in Review

GSA Capital Partners sold out of Abeona Therapeutics (ABEO) in Q2 2025, closing a stake of 63,835 shares — an estimated $304K sold.

GSA Capital Partners first reported a position in ABEO in Q2 2019 and held it in 10 quarters. The position peaked at $607K in Q3 2024. 95 funds tracked by Wall St. Rank hold ABEO as of Q2 2025.

  • GSA Capital Partners reported no remaining Abeona Therapeutics position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 63,835 Abeona Therapeutics shares in Q2 2025, an estimated $304K.
  • GSA Capital Partners first reported a position in Abeona Therapeutics in Q2 2019 and held it in 10 quarters.
  • GSA Capital Partners's Abeona Therapeutics position peaked at $607K in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.